诺和诺德的 CagriSema 2.4 毫克/2.4 毫克在 REIMAGINE 项目的多项研究中均显示出显著降低 HbA1c 和体重的效果。
美国新泽西州普莱恩斯伯勒和丹麦巴格斯沃斯，2026 年 6 月 7 日 /PRNewswire/ -- 诺和诺德 REIMAGINE 1-3 试验的 3 期结果于今日公布，结果显示，2 型糖尿病 (T2D) 成年患者的 HbA1c 和体重显著降低。
该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。
Preguntas frecuentes
Which products are related to this article?
No strongly related product has been identified yet. The match updates automatically when the article or catalog changes.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.
